Brickell Biotech, Inc.
https://brickellbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Brickell Biotech, Inc.
Pharma Spreads Its Bets On Multiple Modalities In Advanced Products
Companies such as Novartis, Roche or Takeda are heavily invested in the advanced therapeutics field, usually spreading their bets across multiple modalities. The remaining challenges offer opportunities for the next wave of innovation to transform the field once again and make a dent in the larger market of common diseases and solid tumors.
Yumanity To Reverse Merge With Kineta Two Years After Its Own Public Debut
After its August 2020 reverse merger, neuroscience-focused Yumanity is calling it quits with two transactions: an asset sale to Janssen and a merger with private cancer immunotherapy firm Kineta.
China's mRNA Shot Shows Benefits Over Older COVID Vaccines
Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.
Asia Deal Watch: Astellas, GO Team Up On Targeted Cancer Therapy
Astellas subsidiary Xyphos will partner with GO to discover novel antibodies against two glycoprotein targets. SciNeuro picks up abandoned GSK programs in cardiovascular medicine for potential use in the neurodegeneration space.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Vical, Inc.
- Vical Incorporated (VICL)